Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31090043 | 0.97 | PTPN1 (0.47) | CTSBCTSLCTSSCTSKPTPN1 | |
| SCHEMBL30918202 | 0.94 | PTPN1 (0.45) | CTSBCTSLCTSSCTSKPTPN1 | |
| SCHEMBL30918284 | 0.94 | PTPN1 (0.45) | CTSBCTSLCTSSCTSKPTPN1 | |
| SCHEMBL31089971 | 0.91 | OPRD1 (0.45) | PTPN1 | |
| SCHEMBL29101925 | 0.88 | KMT2A (0.47) | PTPN1 | |
| SCHEMBL30918231 | 0.88 | KMT2A (0.47) | PTPN1 | |
| SCHEMBL31089986 | 0.88 | KMT2A (0.47) | PTPN1 | |
| SCHEMBL30712765 | 0.88 | KMT2A (0.47) | PTPN1 | |
| SCHEMBL31690598 | 0.86 | PTPN1 (0.41) | PTPN1 | |
| SCHEMBL30918245 | 0.86 | PTPN1 (0.41) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001891-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | KEYMED BIOSCIENCES (CHENGDU) CO., LTD. (CN) | 2026-01-01 | — | — | US | disclosed |
| EP-4623936-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | Keymed Biosciences (Chengdu) Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| WO-2024109840-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | 康诺亚生物医药科技（成都）有限公司 | 2024-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001891-A1 | FUSED RING COMPOUND, CONJUGATE THEREOF AND USE THEREOF | HCCS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1 | CTSB 2017/4885CTSL 2229/4885CTSS 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.